The drugmaker Pfizer said Wednesday it will seek emergency use authorization for its coronavirus vaccine, after it proved 95% effective at preventing COVID-19 in a large clinical trial. Pfizer also reports the vaccine poses no serious safety concerns and appears to prevent severe disease among those recipients who become infected with the coronavirus. The findings have not yet been peer-reviewed, and the vaccine still has to be reviewed by the Food and Drug Administration. It’s not known how long recipients of Pfizer’s vaccine will remain protected against COVID-19 or whether the vaccine confers “sterilizing immunity” that would prevent vaccinated people from passing infections along to other people.
Pfizer to Seek Emergency Authorization of COVID-19 Vaccine, Touting 95% Efficacy
HeadlineNov 19, 2020